Center for Molecular and Cellular Toxicology, Division of Pharmacology and Toxicology, College of Pharmacy, University of Texas at Austin, Austin, TX 78712, USA.
Cell Death Differ. 2010 Aug;17(8):1288-301. doi: 10.1038/cdd.2010.9. Epub 2010 Feb 19.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potentially useful anticancer agent with exquisite selectivity for cancer cells. Unfortunately, many cancers show or acquire resistance to TRAIL. In this study we report that TRAIL activates a TGF-beta-activated kinase 1 --> mitogen-activated protein kinase (MAPK) kinase 3 (MKK3)/MKK6 --> p38 pathway in prostate cancer cells that transcriptionally upregulates expression of the antiapoptotic BCL-2 family member MCL-1. TRAIL alone triggered robust formation of the 'death-inducing signaling complex' (DISC), activation of the initiator caspase-8, and truncation of the BH3-only protein BID (tBID). Nevertheless, simultaneous disruption of the p38 MAPK pathway was required to suppress MCL-1 expression, thereby allowing tBID to activate the proapoptotic BCL-2 family member BAK and stimulate mitochondrial outer membrane permeabilization (MOMP). Release of the inhibitor-of-apoptosis (IAP) antagonist, Smac/DIABLO, from the intermembrane space was sufficient to promote TRAIL-induced apoptosis, whereas release of cytochrome c and activation of the apoptosome was dispensable. Even after MOMP, however, mitochondrial-generated reactive oxygen species (ROS) activated a secondary signaling pathway, involving c-Jun N-terminal kinases (JNKs), that similarly upregulated MCL-1 expression and partially rescued some cells from death. Thus, stress kinases activated at distinct steps, before and after mitochondrial injury, mediate TRAIL resistance through maintenance of MCL-1 expression.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)是一种潜在有用的抗癌药物,对癌细胞具有极高的选择性。不幸的是,许多癌症表现出或获得了对 TRAIL 的耐药性。在这项研究中,我们报告 TRAIL 在前列腺癌细胞中激活 TGF-β激活激酶 1-->丝裂原激活蛋白激酶(MAPK)激酶 3(MKK3)/MKK6-->p38 途径,转录上调抗凋亡 BCL-2 家族成员 MCL-1 的表达。TRAIL 本身触发了“死亡诱导信号复合物”(DISC)的强烈形成,起始半胱天冬酶-8 的激活,以及 BH3 仅蛋白 BID(tBID)的截断。然而,需要同时破坏 p38 MAPK 途径来抑制 MCL-1 的表达,从而允许 tBID 激活促凋亡 BCL-2 家族成员 BAK 并刺激线粒体外膜通透性(MOMP)。从膜间空间释放凋亡抑制剂(IAP)拮抗剂 Smac/DIABLO,足以促进 TRAIL 诱导的细胞凋亡,而细胞色素 c 的释放和凋亡体的激活则是可有可无的。然而,即使在 MOMP 之后,线粒体产生的活性氧(ROS)也会激活一个涉及 c-Jun N 端激酶(JNKs)的二级信号通路,该通路同样上调 MCL-1 的表达,并部分挽救了一些细胞免于死亡。因此,在线粒体损伤之前和之后的不同步骤激活的应激激酶通过维持 MCL-1 的表达介导 TRAIL 耐药性。